Therapeutic vaccination against human papilloma virus induced malignancies

Current Opinion in Immunology

Volumn 23, Issue 2, 2011, Pages 252-257

  van der Burg, Sjoerd H ^a   Melief, Cornelis JM ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CHEMOKINE RECEPTOR CXCR4; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; IMIQUIMOD; INTERLEUKIN 10; RETINOIC ACID; TRANSCRIPTION FACTOR FOXP3;

CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELLULAR IMMUNITY; ENZYME RELEASE; HUMAN; IMMUNOREACTIVITY; IMMUNOREGULATION; IMMUNOTHERAPY; LYMPHOCYTE FUNCTION; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TH1 CELL; UTERINE CERVIX CARCINOMA IN SITU; VAGINAL INTRAEPITHELIAL NEOPLASIA; VULVAR INTRAEPITHELIAL NEOPLASIA; WART VIRUS;

CANCER VACCINES; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; T-LYMPHOCYTES;

EID: 79953113656     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2010.12.010     Document Type: Review

References (54)

1. Kobayashi A., Weinberg V., Darragh T., Smith-McCune K. Evolving immunosuppressive microenvironment during human cervical carcinogenesis. Mucosal Immunol 2008, 1:412-420.
2. Scott M.E., Ma Y., Kuzmich L., Moscicki A.B. Diminished IFN-gamma and IL-10 and elevated Foxp3 mRNA expression in the cervix are associated with CIN 2 or 3. Int J Cancer 2009, 124:1379-1383.
3. Syrjanen S., Naud P., Sarian L., Derchain S., Roteli-Martins C., Longatto-Filho A., Tatti S., Branca M., Erzen M., Hammes L.S., et al. Immunosuppressive cytokine Interleukin-10 (IL-10) is upregulated in high-grade CIN but not associated with high-risk human papillomavirus (HPV) at baseline, outcomes of HR-HPV infections or incident CIN in the LAMS cohort. Virchows Arch 2009, 455:505-515.
4. Piersma S.J., Jordanova E.S., van Poelgeest M.I., Kwappenberg K.M., van der Hulst J.M., Drijfhout J.W., Melief C.J., Kenter G.G., Fleuren G.J., Offringa R., et al. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 2007, 67:354-361.
5. Bontkes H.J., de Gruijl T.D., Walboomers J.M., van den Muysenberg A.J., Gunther A.W., Scheper R.J., Meijer C.J., Kummer J.A. Assessment of cytotoxic T-lymphocyte phenotype using the specific markers granzyme B and TIA-1 in cervical neoplastic lesions. Br J Cancer 1997, 76:1353-1360.
6. Karim R., Jordanova E.S., Piersma S.J., Kenter G.G., Chen L., Boer J.M., Melief C.J., van der Burg S.H. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res 2009, 15:6341-6347.
7. Jaafar F., Righi E., Lindstrom V., Linton C., Nohadani M., Van Noorden S., Lloyd T., Poznansky J., Stamp G., Dina R., et al. Correlation of CXCL12 expression and FoxP3+ cell infiltration with human papillomavirus infection and clinicopathological progression of cervical cancer. Am J Pathol 2009, 175:1525-1535.
8. Hammes L.S., Tekmal R.R., Naud P., Edelweiss M.I., Kirma N., Valente P.T., Syrjanen K.J., Cunha-Filho J.S. Macrophages, inflammation and risk of cervical intraepithelial neoplasia (CIN) progression-clinicopathological correlation. Gynecol Oncol 2007, 105:157-165.
9. Kryczek I., Liu R., Wang G., Wu K., Shu X., Szeliga W., Vatan L., Finlayson E., Huang E., Simeone D., et al. FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res 2009, 69:3995-4000.
10. Munn D.H., Mellor A.L. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007, 117:1147-1154.
11. Lepique A.P., Daghastanli K.R., Cuccovia I.M., Villa L.L. HPV16 tumor associated macrophages suppress antitumor T cell responses. Clin Cancer Res 2009, 15:4391-4400.
12. Zijlmans H.J., Fleuren G.J., Baelde H.J., Eilers P.H., Kenter G.G., Gorter A. The absence of CCL2 expression in cervical carcinoma is associated with increased survival and loss of heterozygosity at 17q11.2. J Pathol 2006, 208:507-517.
13. Battaglia A., Buzzonetti A., Baranello C., Ferrandina G., Martinelli E., Fanfani F., Scambia G., Fattorossi A. Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer. Cancer Immunol Immunother 2009, 58:1663-1673.
14. Woo Y.L., Sterling J., Damay I., Coleman N., Crawford R., van der Burg S.H., Stanley M. Characterising the local immune responses in cervical intraepithelial neoplasia: a cross-sectional and longitudinal analysis. BJOG 2008, 115:1616-1621.
15. Ovestad I.T., Gudlaugsson E., Skaland I., Malpica A., Kruse A.J., Janssen E.A., Baak J.P. Local immune response in the microenvironment of CIN2-3 with and without spontaneous regression. Mod Pathol 2010.
16. Jordanova E.S., Gorter A., Ayachi O., Prins F., Durrant L.G., Kenter G.G., van der Burg S.H., Fleuren G.J. Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients?. Clin Cancer Res 2008, 14:2028-2035.
17. Kloth J.N., Gorter A., Fleuren G.J., Oosting J., Uljee S., ter Haar N., Dreef E.J., Kenter G.G., Jordanova E.S. Elevated expression of SerpinA1 and SerpinA3 in HLA-positive cervical carcinoma. J Pathol 2008, 215:222-230.
18. Woo Y.L., van den Hende M., Sterling J.C., Coleman N., Crawford R.A., Kwappenberg K.M., Stanley M.A., van der Burg S.H. A prospective study on the natural course of low-grade squamous intraepithelial lesions and the presence of HPV16 E2-,E6- and E7-specific T-cell responses. Int J Cancer 2010, 126:133-141.
19. Farhat S., Nakagawa M., Moscicki A.B. Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzyme-linked immunospot in women with cleared or persistent human papillomavirus infection. Int J Gynecol Cancer 2009, 19:508-512.
20. de Vos van Steenwijk P.J., Piersma S.J., Welters M.J., van der Hulst J.M., Fleuren G., Hellebrekers B.W., Kenter G.G., van der Burg S.H. Surgery followed by persistence of high-grade squamous intraepithelial lesions is associated with the induction of a dysfunctional HPV16-specific T-cell response. Clin Cancer Res 2008, 14:7188-7195.
21. Trimble C.L., Peng S., Thoburn C., Kos F., Wu T.C. Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3. Cancer Immunol Immunother 2010, 59:799-803.
22. Seresini S., Origoni M., Lillo F., Caputo L., Paganoni A.M., Vantini S., Longhi R., Taccagni G., Ferrari A., Doglioni C., et al. IFN-gamma produced by human papilloma virus-18 E6-specific CD4+ T cells predicts the clinical outcome after surgery in patients with high-grade cervical lesions. J Immunol 2007, 179:7176-7183.
23. Bourgault Villada I., Moyal Barracco M., Berville S., Bafounta M.L., Longvert C., Premel V., Villefroy P., Jullian E., Clerici T., Paniel B., et al. Human papillomavirus 16-specific T cell responses in classic HPV-related vulvar intra-epithelial neoplasia. Determination of strongly immunogenic regions from E6 and E7 proteins. Clin Exp Immunol 2010, 159:45-56.
24. van Poelgeest M.I., van Seters M., van Beurden M., Kwappenberg K.M., Heijmans-Antonissen C., Drijfhout J.W., Melief C.J., Kenter G.G., Helmerhorst T.J., Offringa R., et al. Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin Cancer Res 2005, 11:5273-5280.
25. Piersma S.J., Welters M.J., van der Hulst J.M., Kloth J.N., Kwappenberg K.M., Trimbos B.J., Melief C.J., Hellebrekers B.W., Fleuren G.J., Kenter G.G., et al. Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element. Int J Cancer 2008, 122:486-494.
26. de Vos van Steenwijk P.J., Heusinkveld M., Ramwadhdoebe T.H., Lowik M.J., van der Hulst J.M., Goedemans R., Piersma S.J., Kenter G.G., van der Burg S.H. An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer. Cancer Res 2010, 70:2707-2717.
27. van der Burg S.H., Piersma S.J., de Jong A., van der Hulst J.M., Kwappenberg K.M., van den Hende M., Welters M.J., Van Rood J.J., Fleuren G.J., Melief C.J., et al. Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci USA 2007, 104:12087-12092.
28. Heusinkveld M., Welters M.J., van Poelgeest M.I., van der Hulst J.M., Melief C.J., Fleuren G.J., Kenter G.G., van der Burg S.H. The detection of circulating Human Papillomavirus (HPV)-specific T cells is associated with improved survival of patients with deeply infiltrating tumors. Int J Cancer 2010.
29. Delgado F.G., Martinez E., Cespedes M.A., Bravo M.M., Navas M.C., Combita Rojas A.L. Increase of human papillomavirus-16 E7-specific T helper type 1 response in peripheral blood of cervical cancer patients after radiotherapy. Immunology 2009, 126:523-534.
30. van Seters M., van Beurden M., ten Kate F.J., Beckmann I., Ewing P.C., Eijkemans M.J., Kagie M.J., Meijer C.J., Aaronson N.K., Kleinjan A., et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med 2008, 358:1465-1473.
31. Terlou A., van Seters M., Kleinjan A., Heijmans-Antonissen C., Santegoets L.A., Beckmann I., van Beurden M., Helmerhorst T.J., Blok L.J. Imiquimod induced clearance of HPV is associated with normalization of immune cell counts in usual type vulvar intraepithelial neoplasia. Int J Cancer 2010.
32. Winters U., Daayana S., Lear J.T., Tomlinson A.E., Elkord E., Stern P.L., Kitchener H.C. Clinical and immunologic results of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia. Clin Cancer Res 2008, 14:5292-5299.
33. Kenter G.G., Welters M.J., Valentijn A.R., Lowik M.J., Berends-van der Meer D.M., Vloon A.P., Essahsah F., Fathers L.M., Offringa R., Drijfhout J.W., et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009, 361:1838-1847.
34. Welters M.J., Kenter G.G., de Vos van Steenwijk P.J., Lowik M.J., Berends-van der Meer D.M., Essahsah F., Stynenbosch L.F., Vloon A.P., Ramwadhdoebe T.H., Piersma S.J., et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci USA 2010, 107:11895-11899.
35. Daayana S., Elkord E., Winters U., Pawlita M., Roden R., Stern P.L., Kitchener H.C. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer 2010, 102:1129-1136.
36. Oldenhove G., de Heusch M., Urbain-Vansanten G., Urbain J., Maliszewski C., Leo O., Moser M. CD4+ CD25+ regulatory T cells control T helper cell type 1 responses to foreign antigens induced by mature dendritic cells in vivo. J Exp Med 2003, 198:259-266.
37. Nakanishi Y., Lu B., Gerard C., Iwasaki A. CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature 2009, 462:510-513.
38. Santin A.D., Bellone S., Palmieri M., Zanolini A., Ravaggi A., Siegel E.R., Roman J.J., Pecorelli S., Cannon M.J. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J Virol 2008, 82:1968-1979.
39. Kenter G.G., Welters M.J., Valentijn A.R., Lowik M.J., Berends-van der Meer D.M., Vloon A.P., Drijfhout J.W., Wafelman A.R., Oostendorp J., Fleuren G.J., et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 2008, 14:169-177.
40. Welters M.J., Kenter G.G., Piersma S.J., Vloon A.P., Lowik M.J., Berends-van der Meer D.M., Drijfhout J.W., Valentijn A.R., Wafelman A.R., Oostendorp J., et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 2008, 14:178-187.
41. Cao Y., Zhao J., Lei Z., Shen S., Liu C., Li D., Liu J., Shen G.X., Zhang G.M., Feng Z.H., et al. Local accumulation of FOXP3+ regulatory T cells: evidence for an immune evasion mechanism in patients with large condylomata acuminata. J Immunol 2008, 180:7681-7686.
42. Zhao J., Cao Y., Lei Z., Yang Z., Zhang B., Huang B. Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res 2010, 70:4850-4858.
43. Cao Y., Zhao J., Yang Z., Cai Z., Zhang B., Zhou Y., Shen G.X., Chen X., Li S., Huang B. CD4+FOXP3+ regulatory T cell depletion by low-dose cyclophosphamide prevents recurrence in patients with large condylomata acuminata after laser therapy. Clin Immunol 2010, 136:21-29.
44. Curran M.A., Montalvo W., Yagita H., Allison J.P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010, 107:4275-4280.
45. Hoffmann C., Stanke J., Kaufmann A.M., Loddenkemper C., Schneider A., Cichon G. Combining T-cell vaccination and application of agonistic anti-GITR mAb (DTA-1) induces complete eradication of HPV oncogene expressing tumors in mice. J Immunother 2010, 33:136-145.
46. Sharma R.K., Elpek K.G., Yolcu E.S., Schabowsky R.H., Zhao H., Bandura-Morgan L., Shirwan H. Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors. Cancer Res 2009, 69:4319-4326.
47. Tseng C.W., Hung C.F., Alvarez R.D., Trimble C., Huh W.K., Kim D., Chuang C.M., Lin C.T., Tsai Y.C., He L., et al. Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res 2008, 14:3185-3192.
48. Sin J.I., Kim J.M., Bae S.H., Lee I.H., Park J.S., Ryoo H.M. Adoptive transfer of human papillomavirus E7-specific CTL enhances tumor chemoresponse through the perforin/granzyme-mediated pathway. Mol Ther 2009, 17:906-913.
49. Spanos W.C., Nowicki P., Lee D.W., Hoover A., Hostager B., Gupta A., Anderson M.E., Lee J.H. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Arch Otolaryngol Head Neck Surg 2009, 135:1137-1146.
50. Tseng C.W., Trimble C., Zeng Q., Monie A., Alvarez R.D., Huh W.K., Hoory T., Wang M.C., Hung C.F., Wu T.C. Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts. Cancer Immunol Immunother 2009, 58:737-748.
51. Wang J., Huizinga T.W., Toes R.E. De novo generation and enhanced suppression of human CD4+CD25+ regulatory T cells by retinoic acid. J Immunol 2009, 183:4119-4126.
52. Song X., Guo W., Cui J., Qian X., Yi L., Chang M., Cai Q., Zhao Q. A tritherapy combination of a fusion protein vaccine with immune-modulating doses of sequential chemotherapies in an optimized regimen completely eradicates large tumors in mice. Int J Cancer 2010, n/a. 10.1002/ijc. 25451.
53. Haas A.R., Sun J., Vachani A., Wallace A.F., Silverberg M., Kapoor V., Albelda S.M. Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin Cancer Res 2006, 12:214-222.
54. Kim S., Buchlis G., Fridlender Z.G., Sun J., Kapoor V., Cheng G., Haas A., Cheung H.K., Zhang X., Corbley M., et al. Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. Cancer Res 2008, 68:10247-10256.